Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay JO, Beckerich F, Bourhis JH, Detrait M, Vigouroux S, François S, Legrand F, Guillaume T, Mohty M; SFGM-TC. Chevallier P, et al. Among authors: guillaume t. Cancer Med. 2016 Nov;5(11):3068-3076. doi: 10.1002/cam4.880. Epub 2016 Oct 17. Cancer Med. 2016. PMID: 27748046 Free PMC article.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Among authors: guillaume t. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
Cahu X, Mohty M, Faucher C, Chevalier P, Vey N, El-Cheikh J, Guillaume T, Furst S, Delaunay J, Ayari S, Moreau P, Gastaut JA, Harousseau JL, Blaise D. Cahu X, et al. Among authors: guillaume t. Bone Marrow Transplant. 2008 Nov;42(10):689-91. doi: 10.1038/bmt.2008.231. Epub 2008 Aug 4. Bone Marrow Transplant. 2008. PMID: 18679370 No abstract available.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. Among authors: guillaume t. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, Avet-Loiseau H, Mohty M, Harousseau JL, Garand R. Chevallier P, et al. Among authors: guillaume t. Br J Haematol. 2008 Dec;143(5):744-6. doi: 10.1111/j.1365-2141.2008.07153.x. Br J Haematol. 2008. PMID: 19036018 Free article. No abstract available.
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
Cahu X, Rialland F, Touzeau C, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Cahu X, et al. Among authors: guillaume t. Biol Blood Marrow Transplant. 2009 Dec;15(12):1531-7. doi: 10.1016/j.bbmt.2009.07.021. Epub 2009 Sep 25. Biol Blood Marrow Transplant. 2009. PMID: 19896076 Free article.
Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source.
Chevallier P, Hebia-Fellah I, Planche L, Guillaume T, Bressolette-Bodin C, Coste-Burel M, Rialland F, Mohty M, Imbert-Marcille BM. Chevallier P, et al. Among authors: guillaume t. Bone Marrow Transplant. 2010 Jul;45(7):1204-11. doi: 10.1038/bmt.2009.326. Epub 2009 Nov 23. Bone Marrow Transplant. 2010. PMID: 19935727
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Malard F, et al. Among authors: guillaume t. Biol Blood Marrow Transplant. 2010 Jan;16(1):28-34. doi: 10.1016/j.bbmt.2009.08.010. Epub 2009 Oct 1. Biol Blood Marrow Transplant. 2010. PMID: 20053329 Free article.
234 results